Rona Therapeutics has garnered $33 million in a Series A round of financing. In a separate development, Chinese genomics company Singleron Biotechnologies has acquired Singapore’s Proteona.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in